Are you interested in incorporating MR imaging biomarkers to quantify brain structures into your current clinical review for the detection and evaluation of neurodegenerative conditions?

Visit us at booth AI-20 in the Expo X1 Gallery of the European Congress of Radiology in Vienna, from February 28 to March 3, 2019.

Receive a demo of our brain imaging analysis software and see how products have proven to provide supportive information to physicians in their aid of clinical assessment, treatment planning, and disease progression for monitoring patients.’ automated solutions offer physicians and researchers the ability to easily examine volumetric imaging biomarkers, which can be helpful in the initial and ongoing evaluation of cognitive psychological, and/or behavioral impairments, seizure evaluation, and lesion load monitoring.

  • Quantify measurements of segmentable brain structures with NeuroQuant
  • Quantify measurements of FLAIR lesions and brain structures with LesionQuant
  • Quantify measurements of FDG and Florbetapir radiotracing in native patient brain space with PETQuant

In addition to quickly delivering accurate quantified brain structure measurements compared to age and sex-matched normative reference data, products also provide color-coded segmented brain structure images for easy review in PACS or DICOM viewer.

NeuroQuant and its LesionQuant module are FDA cleared, CE marked, and Health Canada, Korea, and Australia licensed for clinical use. PETQuant is for research use only.